Stay updated on Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial

Sign up to get notified when there's something new on the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Difference
    0.3%
    Check dated 2025-05-08T07:39:04.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-05-01T04:23:02.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Difference
    0.4%
    Check dated 2025-04-23T19:41:48.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    The webpage has undergone significant content changes, particularly in the study details for Chronic Lymphocytic Leukemia (CLL), including the removal of extensive background information and eligibility criteria, while retaining some key identifiers and study locations.
    Difference
    49%
    Check dated 2025-04-16T14:28:33.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-09T09:21:17.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.4%
    Check dated 2025-04-01T23:24:23.000Z thumbnail image

Stay in the know with updates to Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page.